FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer
Posted OnAugust 29, 2023 byOn June 20, 2023, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).Read More…
2023 Grant Recipients
Posted OnJune 30, 2023 byCureBRCA Funds BRCA Prostate Cancer Research – Funded research includes grants to U.S. and international academic institutions: projects include research, screening, treatment, and outreach efforts for men with BRCA genetic mutations.Read More…
Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer
Posted OnApril 27, 2023 byHelicobacter pylori infection is a well-known risk factor for gastric cancer. However, the contribution of germline pathogenic variants in cancer-predisposing genes and their effect, when combined with H. pylori infection, on the risk of gastric cancer has not been widely evaluated.Read More…
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers
Posted OnMarch 29, 2023 bySeveral studies have reported the association of germline BRCA2 (gBRCA2) mutations with poor clinical outcomes in prostate cancer (PCa), but the impact of concurrent somatic events on gBRCA2 carriers survival and disease progression is unknown.Read More…
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
Posted OnOctober 31, 2022 byNewly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
New BRCA-targeting drug could offer hope in treating advanced prostate cancer
Posted OnOctober 14, 2022 byNewly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response
Posted OnJuly 7, 2022 byEpigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.Read More…
Health News – Why men should be tested for BRCA gene
Posted OnJune 28, 2022 byIt’s a genetic mutation that could put you at risk for certain cancers. While most people associate BRCA with breast cancer, the gene can carry risks for both men and women.
PARP Inhibitors – Effective in Men with BRCA-Mutant Prostate Cancer
Posted OnFebruary 14, 2022 byMen with prostate cancer have genomic defects that can be targeted with PARP Inhibitors. All men should undergo genomic testing.
